Brief: Lantern Pharma Confirms Panna Sharma Continues To Serve As President And CEO Alerts Investors To False Third-Party Report
27/03/2026 23:24
March 27 (Reuters) - Lantern Pharma Inc LTRN.O: LANTERN PHARMA CONFIRMS PANNA SHARMA CONTINUES TO SERVE AS PRESIDENT AND CEO; ALERTS INVESTORS TO FALSE THIRD-PARTY REPORT LANTERN PHARMA INC: INTENDS TO PURSUE ALL AVAILABLE LEGAL REMEDIES AND IS CONSIDERING REFERRING THIS MATTER TO THE APPROPRIATE REGULATORY AUTHORITIES Source text: ID:nBw7FR85Wa Further company coverage: LTRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments